Meeting
2014 ASCO Annual Meeting
Comparison of breast cancer recurrence and outcome patterns between patients treated in 1986-1992 and 2004-2008.
Authors
Rachel Jorge Dino Cossetti
BC Cancer Agency, Vancouver, BC, Canada
Rachel Jorge Dino Cossetti , Scott Tyldesley , Caroline Speers , Karen A. Gelmon
Organizations
BC Cancer Agency, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada
Research Funding
No funding sources reported
Background: Different patterns of breast cancer (BC) recurrence overtime have been reported according to estrogen receptor (ER) status. We report a change in BC recurrence patterns. Methods: Females with biopsy proven BC, stages I-III, treated at the BCCA 1986-1992 (cohort 1 – C1) and mid 2004-2008 (cohort 2 – C2), with known ER and HER2 status were eligible. Data was prospectively collected. C2 cases were matched to C1 by random case selection for grade and stage to adjust for imbalances. Endpoints were annual hazard rates of recurrence (HRR) and annual hazard rates of death (HRD). Results: After random sampling, 10,283 pts were included: 3672 in C1 and 6611 in C2. BC subtypes in C1 and C2 were, respectively, ER+/HER2-: 71.2 vs 64.8%; ER+/HER2+: 6.7 vs 11.7%; ER-/HER2+: 6.5 vs 8.2%; ER-/HER2-: 15.5 vs 15.3%. The HRR per yearly interval (up to year 9) for all subtypes have halved in C2. For ER+/HER2- BC, HRR in C2 was half of the HRR in C1. Differences in HRR between C1 and 2 were greater in the initial 5 intervals for HER2+ and triple-negative (TN) BC. The HRD have also decreased, but to a lesser extent. Conclusions: Outcomes have improved for all BC subtypes, but particularly for HER2+ and TN BC. The early spike in disease recurrence has markedly decreased. These contemporary hazard rates are important for treatment decisions and patient discussions, but also for planning of early BC trials.
| HRR (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yearly interval | 0-1 | 1-2 | 2-3 | 3-4 | 4-5 | 5-6 | 6-7 | 7-8 | 8-9 | |
| Cohort 1 | 4.7±0.4 | 8.8±0.5 | 6.8±0.5 | 5.0±0.4 | 4.2±0.4 | 3.7±0.4 | 3.0±0.4 | 3.1±0.4 | 1.8±0.3 | |
| Cohort 2 | 2.7±0.2 | 4.0±0.3 | 3.6±0.2 | 2.6±0.2 | 2.0±0.2 | 1.3±0.2 | 1.2±0.2 | 1.2±0.3 | 0.3±0.3 | |
| ER+/HER2- | C1 C2 |
2.7±0.3 | 6.2±0.5 | 5.0±0.5 | 4.3±0.5 | 4.1±0.5 | 4.1±0.5 | 3.3±0.4 | 3.4±0.5 | 1.9±0.4 |
| 1.5±0.2 | 2.5±0.2 | 3.0±0.3 | 2.2±0.2 | 1.9±0.2 | 1.4±0.2 | 1.7±0.3 | 1.3±0.4 | 0.4±0.4 | ||
| ER+/HER2+ | C1 C2 |
6.7±1.7 | 13.7±2.5 | 12.1±2.6 | 21.6±2.6 | 6.9±2.2 | 3.7±1.7 | 3.2±1.6 | 4.3±1.9 | 2.8±1.6 |
| 2.5±0.6 | 3.1±0.7 | 3.9±0.7 | 3.0±0.7 | 2.7±0.7 | 1.8±0.6 | 0.3±0.3 | 0.7±0.7 | 0 | ||
| ER-/HER2+ | C1 C2 |
13.9±2.5 | 23.6±3.6 | 17.0±3.4 | 7.8±2.5 | 6.8±2.4 | 2.7±1.6 | 1.8±1.3 | 1.9±1.3 | 2.0±1.4 |
| 4.0±0.9 | 8.3±1.3 | 5.5±1.1 | 3.0±0.8 | 1.3±0.6 | 0.3±0.3 | 0 | 1.7±1.2 | 0 | ||
| TNBC | C1 C2 |
9.4±1.3 | 14.6±1.7 | 11.0±1.6 | 5.3±1.2 | 2.5±0.8 | 1.5±0.7 | 1.8±0.7 | 1.6±0.7 | 1.3±0.6 |
| 7.3±0.9 | 9.1±1.0 | 5.5±0.8 | 3.8±0.7 | 2.0±0.5 | 0.7±0.4 | 0.5±0.3 | 0.9±0.6 | 0 | ||
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 521)
DOI
10.1200/jco.2014.32.15_suppl.521
Abstract #
521
Poster Bd #
10
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Annual Meeting
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.
First Author: Shipra Gandhi
Abstract
2023 ASCO Annual Meeting
Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer.
First Author: Lyudmila Zhukova
Abstract
2023 ASCO Annual Meeting
Role of plasma circulating HER2/EFTUD2 ratio in predicting pathological complete response (pCR) after neoadjuvant dual anti-HER2 therapy in HER2-positive breast cancer (HER2+ BC).
First Author: Jeffrey CH Chan
Abstract
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin